Standard BioTools

Standard BioTools Current Liabilities

The Current Liabilities of Standard BioTools (LAB) as of Sep 21, 2026 is 69.36 M USD. In the previous year, Current Liabilities was 80.73 M USD — a change of -14.08% (lower).

Current Liabilities

69.36 MUSD

YoY

-14.08%

Last updated:

Current Liabilities of Standard BioTools is 2026 69.36 M USD. Current Liabilities of Standard BioTools was 2025 80.73 M USD. It decreases by -14.08% lower compared to the previous year.

The Standard BioTools Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
48.22 M USD
Jan 1, 2019
34.20 M USD
Jan 1, 2020
66.88 M USD
Jan 1, 2021
56.07 M USD
Jan 1, 2022
48.93 M USD
Jan 1, 2023
176.77 M USD
Jan 1, 2024
80.73 M USD
Jan 1, 2025
69.36 M USD
The Standard BioTools Current Liabilities history
YEARCurrent LiabilitiesYoY
69.36 MUSD-14.08%
80.73 MUSD-54.33%
176.77 MUSD+261.24%
48.93 MUSD-12.74%
56.07 MUSD-16.16%
66.88 MUSD+95.59%
34.20 MUSD-29.08%
48.22 MUSD+14.16%
42.24 MUSD+14.97%
36.74 MUSD+4.18%
35.26 MUSD-9.48%
38.96 MUSD+45.18%
26.83 MUSD+58.67%
16.91 MUSD-47.58%
32.26 MUSD+19.15%
27.08 MUSD+102.03%
13.40 MUSD+55.84%
8.60 MUSD-3.62%
8.92 MUSD+45.33%
6.14 MUSD
Access this data via the Eulerpool API

Standard BioTools Stock analysis

What does Standard BioTools do? Fluidigm Corp is a biotechnology company specializing in innovative devices and solutions for DNA sequencing. The company was founded in 1999 in San Francisco and is currently headquartered in South San Francisco. It developed the Microfluidic Technology-Sensor, which allows for handling tiny amounts of fluids in a small space. This technology has enabled researchers to analyze complex samples and collect data with high accuracy. The company operates in two main segments: Analytical Instruments and Sample Preparation. In the Analytical Instruments segment, Fluidigm offers various devices suitable for DNA sequencing, including the Juno, C1, and Biomark platforms. It also provides a wide range of consumables to facilitate sample preparation. The Sample Preparation segment offers products and services to prepare and process samples for analysis, including microfluidic technology chips and modules, single-cell sequencing systems, and products for next-generation sequencing. Fluidigm serves customers in various industries, such as genomics research, cancer research, and medical fields, with a strong presence in North America, Europe, and Asia. The company is known for its continuous investment in research and development, as well as its innovative technologies and patents. Overall, Fluidigm's Microfluidic technology platform allows researchers to collect data in a small space with high accuracy. With a diversified portfolio of products and services, the company is well-positioned to continue growing and expanding its market presence in the coming years. Standard BioTools is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Standard BioTools stock

Current Liabilities of Standard BioTools is 69.36 M USD in 2026.

Current Liabilities of Standard BioTools changed from 80.73 M USD to 69.36 M USD, representing a -14.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Standard BioTools since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Standard BioTools historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Standard BioTools

All Key Metrics — Standard BioTools